In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


This content is currently on FREE ACCESS

 

Clinical aspects: type 2 diabetes, cardiovascular disease and glucagon-like peptide-1 receptor agonists.

Session Discussion: Glucagon-like peptide-1 receptor agonists and changing paradigms in clinical practice

Speaker Marc Pfeffer

Congress : ESC Congress 2018

  • Topic : preventive cardiology
  • Sub-topic : Diabetes and the Heart
  • Session type : Satellite Symposium - Experts on the Spot
  • FP Number : 1987
  • Sponsored by Novo Nordisk A/S

This content is currently on FREE ACCESS

 



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are